Who are the major ELISA analyzers industry players?

Abbott Laboratories, Agilent Technologies, Inc, bioM Read More

Home > Healthcare > Analytical Instruments > Immunoassay > ELISA Analyzers Market

ELISA Analyzers Market Share

Report ID: GMI9569
Published Date: May 2024
Report Format: PDF

Download Free Sample

ELISA Analyzers Market Share

The ELISA analyzers sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

ELISA Analyzers Market Companies

Some of the eminent market participants operating in the ELISA analyzers industry include:

Abbott Laboratories
Agilent Technologies, Inc.
bioMérieux S.A.
Bio-Rad Laboratories, Inc.
Danaher Corporation
DiaSorin S.p.A.
DYNEX Technologies
Erba Mannheim
F. Hoffmann-La Roche Ltd
Merck KGaA
PerkinElmer, Inc.
Randox Laboratories Ltd.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Tecan Group Ltd.
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global ELISA analyzers market size was valued at around USD 587.1 million in 2023 and is estimated to grow at 4.2% CAGR from 2024 to 2032, driven by technological advancements in diagnostic testing.

The automated ELISA analyzers segment accounted for USD 352.9 million in 2023 and will expand rapidly through 2032, attributed to the inherent advantages of automation in streamlining the ELISA process and reducing manual intervention.

The U.S. ELISA analyzers market held a decent market share in 2023 and is forecasted to reach USD 305.2 million by 2032, owing to an aging population which is more susceptible to chronic diseases.

Abbott Laboratories, Agilent Technologies, Inc, bioM